Jung Sung-Hoon, Lee Je-Jung
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Blood Res. 2022 Apr 30;57(S1):62-66. doi: 10.5045/br.2022.2022033.
Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell neoplasm developing in 0.5?4% of patients with multiple myeloma (MM). The diagnostic criteria were recently revised from 20% to ≥5% of circulating plasma cells in peripheral blood smears. PCL is classified as primary or secondary; primary PCL is when it presents in patients with no MM. Primary PCL shows clinical and laboratory features at presentation that differ from MM and exhibits a dismal prognosis even with the use of effective agents against MM. Therefore, intensive chemotherapy should be initiated immediately after diagnosis, and autologous stem cell transplantation is recommended for transplant-eligible patients. Maintenance therapy after transplantation may reduce the rate of early relapses. We reviewed the definitions of PCL, revised diagnostic criteria, clinical features, and appropriate initial treatments for primary PCL.
浆细胞白血病(PCL)是一种罕见且侵袭性很强的浆细胞肿瘤,在0.5%至4%的多发性骨髓瘤(MM)患者中发生。其诊断标准最近从外周血涂片循环浆细胞占20%修订为≥5%。PCL分为原发性或继发性;原发性PCL是指在无MM的患者中出现。原发性PCL在初诊时表现出与MM不同的临床和实验室特征,即使使用针对MM的有效药物,其预后也很差。因此,诊断后应立即开始强化化疗,对于适合移植的患者建议进行自体干细胞移植。移植后的维持治疗可能会降低早期复发率。我们回顾了PCL的定义、修订后的诊断标准、临床特征以及原发性PCL的适当初始治疗方法。